Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Study Details
Study Description
Brief Summary
Research Hypothesis: icotinib administered in combination with gemcitabine has an acceptable safety profile in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.The primary objective is to determine the safety profile of icotinib in combination with gemcitabine in subjects with locally advanced, unresectable or metastatic pancreatic adenocarcinoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: icotinib plus gemcitabine Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity. Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks. |
Drug: icotinib
Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
Other Names:
Drug: Gemcitabine
Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- The number of patients who suffer adverse events [24 months]
Secondary Outcome Measures
- Tumor response assessed by RECIST 1.1 [3 months]
- Progression-free survival [4 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Locally advanced, unresectable or metastatic pancreatic cancer by histologic or cytologic confirmation without previous chemotherapy or target therapy.
-
ECOG Performance Status of 0 to 1.
-
Adequate organ function as defined by study-specified laboratory tests.
-
Signed informed consent form.
-
Willing and able to comply with study procedures.
Exclusion Criteria:
-
Previous chemotherapy or target therapy.
-
Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions.
-
Systemically active steroids.
-
Another investigational product within 28 days prior to receiving study drug.
-
Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug.
-
Infection with HIV, hepatitis B or C at screening.
-
Pregnant or lactating.
-
Conditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Cancer Hospital of Harbin Medical University | Harbin | Heilongjiang | China | 150081 |
2 | Bethune First Hospital of Jilin University | Changchun | Jilin | China | 150081 |
3 | First Affiliated Hospital of China Medical University | Shenyang | Liaoning | China | 150081 |
Sponsors and Collaborators
- Betta Pharmaceuticals Co., Ltd.
Investigators
- Principal Investigator: Yanqiao Zhang, MD, Cancer Hospital of Harbin Medical University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BD-IC-IV70